These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 8313182)
21. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa. Cachia PJ; Hodges RS Biopolymers; 2003; 71(2):141-68. PubMed ID: 12767116 [TBL] [Abstract][Full Text] [Related]
22. Piperacillin and gentamicin suppress Pseudomonas aeruginosa pyoderma acuta complicated by diabetes mellitus. Higaki S; Kitagawa T; Takashima H; Makino T; Morohashi M; Yamagishi T Int J Antimicrob Agents; 2004 Nov; 24(5):519-20. PubMed ID: 15519489 [No Abstract] [Full Text] [Related]
23. [Epidemiological profile and antibiotic susceptibility of Pseudomonas aeruginosa isolates within the burned patient hospitalized in the intensive care burn unit]. Lamia T; Bousselmi K; Saida BR; Allah MA Tunis Med; 2007 Feb; 85(2):124-7. PubMed ID: 17665658 [TBL] [Abstract][Full Text] [Related]
24. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. Ciofu O APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154 [TBL] [Abstract][Full Text] [Related]
25. Community-acquired Pseudomonas aeruginosa urinary tract infections in children hospitalized in a tertiary center: relative frequency, risk factors, antimicrobial resistance and treatment. Marcus N; Ashkenazi S; Samra Z; Cohen A; Livni G Infection; 2008 Oct; 36(5):421-6. PubMed ID: 18795227 [TBL] [Abstract][Full Text] [Related]
26. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Harris A; Torres-Viera C; Venkataraman L; DeGirolami P; Samore M; Carmeli Y Clin Infect Dis; 1999 May; 28(5):1128-33. PubMed ID: 10452647 [TBL] [Abstract][Full Text] [Related]
27. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562 [TBL] [Abstract][Full Text] [Related]
28. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. Paladino JA; Sunderlin JL; Forrest A; Schentag JJ J Antimicrob Chemother; 2003 Sep; 52(3):457-63. PubMed ID: 12888598 [TBL] [Abstract][Full Text] [Related]
29. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study. Vuotto F; Berthon C; Lemaitre N; Duhamel A; Balkaran S; Le Ray E; Micol JB; Faure K; Alfandari S Am J Infect Control; 2013 Jun; 41(6):527-30. PubMed ID: 23219670 [TBL] [Abstract][Full Text] [Related]
30. Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome. Nguyen LH; Hsu DI; Ganapathy V; Shriner K; Wong-Beringer A J Antimicrob Chemother; 2008 Mar; 61(3):714-20. PubMed ID: 18222951 [TBL] [Abstract][Full Text] [Related]
34. Netilmicin in the treatment of Pseudomonas bacteremia. Lorber RR; Linzmayer MI Clin Ther; 1985; 7(3):338-46. PubMed ID: 3922616 [TBL] [Abstract][Full Text] [Related]
35. Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia. Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW Clin Microbiol Infect; 2005 May; 11(5):415-8. PubMed ID: 15819873 [TBL] [Abstract][Full Text] [Related]
36. Fatal multi-resistant Pseudomonas aeruginosa septicemia outbreak in a neonatal intensive care unit in Trinidad. Orrett FA Ethiop Med J; 2000 Apr; 38(2):85-91. PubMed ID: 11144887 [TBL] [Abstract][Full Text] [Related]
37. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Rahal JJ Clin Infect Dis; 2006 Sep; 43 Suppl 2():S95-9. PubMed ID: 16894522 [TBL] [Abstract][Full Text] [Related]
38. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Obritsch MD; Fish DN; MacLaren R; Jung R Pharmacotherapy; 2005 Oct; 25(10):1353-64. PubMed ID: 16185180 [TBL] [Abstract][Full Text] [Related]
39. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Ozkurt Z; Ertek M; Erol S; Altoparlak U; Akcay MN Burns; 2005 Nov; 31(7):870-3. PubMed ID: 15975720 [TBL] [Abstract][Full Text] [Related]
40. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. Hansen CR; Pressler T; Høiby N J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]